Schadendorf, D., Wong, M. K., Beasley, G. M., Pavlick, A. C., Harrington, K. J., Chmielowski, B., … Milhem, M. M. (2025). 1661P Efficacy and safety of RP1 + nivolumab (nivo) in patients with non-melanoma skin cancer (NMSC). In Annals of Oncology (Vol. 36, pp. S983–S984). Elsevier BV. https://doi.org/10.1016/j.annonc.2025.08.2289

Schadendorf, D., M. K. Wong, G. M. Beasley, A. C. Pavlick, K. J. Harrington, B. Chmielowski, J. J. Niu, et al. “1661P Efficacy and safety of RP1 + nivolumab (nivo) in patients with non-melanoma skin cancer (NMSC).” In Annals of Oncology, 36:S983–84. Elsevier BV, 2025. https://doi.org/10.1016/j.annonc.2025.08.2289.

Schadendorf D, Wong MK, Beasley GM, Pavlick AC, Harrington KJ, Chmielowski B, et al. 1661P Efficacy and safety of RP1 + nivolumab (nivo) in patients with non-melanoma skin cancer (NMSC). In: Annals of Oncology. Elsevier BV; 2025. p. S983–4.

Schadendorf, D., et al. “1661P Efficacy and safety of RP1 + nivolumab (nivo) in patients with non-melanoma skin cancer (NMSC).” Annals of Oncology, vol. 36, Elsevier BV, 2025, pp. S983–84. Crossref, doi:10.1016/j.annonc.2025.08.2289.

Schadendorf D, Wong MK, Beasley GM, Pavlick AC, Harrington KJ, Chmielowski B, Niu JJ, VanderWalde AM, Bowles TL, Tsai KK, Hall ET, Wise-draper TM, Michels J, Arance AM, Amini Adle M, Zhu J, Viana M, Hou JW, Milhem MM. 1661P Efficacy and safety of RP1 + nivolumab (nivo) in patients with non-melanoma skin cancer (NMSC). Annals of Oncology. Elsevier BV; 2025. p. S983–S984.